Plasma-Derived Therapies: Advancing Lifesaving Care and Expanding the Global Blood Plasma Market
Plasma-derived therapies are a critical pillar of modern biopharmaceutical innovation, offering life-saving treatments for a wide range of rare, chronic, and life-threatening conditions. These therapies are developed from human blood plasma—a protein-rich component of blood—and processed into specialized medicinal products such as immunoglobulins, albumin, and coagulation factors. They play a vital role in treating immune deficiencies, bleeding disorders, and neurological diseases, significantly improving patient survival and quality of life.
The global blood plasma market was valued at USD 31.86 billion in 2024 and is expected to grow at a CAGR of 7.20% from 2025 to 2034, reaching an estimated value of around USD 63.8 billion by 2034.
Understanding Plasma-Derived Therapies
Plasma-derived therapies (PDTs) are medicinal treatments created through the fractionation and purification of human plasma. The process involves separating plasma into individual protein components, which are then purified and manufactured into therapeutic products.
Key plasma-derived medicines include:
- Immunoglobulins (IVIG/SCIG) – used for immune deficiencies and autoimmune diseases
- Albumin – used in trauma, surgery, and liver disease treatment
- Coagulation factors – essential for hemophilia and bleeding disorder management
- Alpha-1 antitrypsin – used in genetic lung disease treatment
- C1 esterase inhibitors – used for hereditary angioedema
These therapies are considered essential medicines by global health organizations due to their ability to treat complex and often rare diseases with limited alternative options.
How Plasma-Derived Therapies Work
Plasma-derived therapies begin with the collection of plasma from healthy donors. The plasma undergoes a highly controlled fractionation process, where proteins are separated based on their physical and chemical properties. These proteins are then purified, tested for safety, and formulated into injectable or infusion-based medications.
Because these therapies are derived from human biological material, they require stringent safety protocols to ensure viral inactivation, pathogen removal, and consistent therapeutic quality. Advances in biotechnology and manufacturing processes have significantly improved yield, safety, and scalability.
Key Growth Drivers of the Plasma-Derived Therapy Market
Rising Prevalence of Immune and Rare Diseases
The increasing incidence of primary immunodeficiency disorders, hemophilia, and autoimmune conditions is one of the strongest drivers of plasma-derived therapy demand. Many of these diseases require lifelong treatment, creating sustained demand for immunoglobulins and related products.
Expanding Use of Immunoglobulin Therapies
Immunoglobulins represent the largest and fastest-growing segment of plasma-derived products due to their broad therapeutic applications in neurology, immunology, and infectious diseases. Their versatility continues to expand clinical adoption globally.
Growth in Plasma Collection Infrastructure
Global expansion of plasma donation centers and fractionation facilities is improving supply chain stability. Major industry players are investing heavily in plasma collection networks and manufacturing capacity to meet rising demand.
Technological Advancements in Fractionation
Modern plasma fractionation technologies have improved efficiency, safety, and yield, enabling manufacturers to produce higher volumes of therapies from limited plasma supply.
Aging Population and Chronic Disease Burden
An aging global population is contributing to higher rates of chronic diseases, increasing the need for long-term biologic therapies derived from plasma.
Segment Analysis of the Blood Plasma Market
By Product Type
The market is primarily segmented into:
- Immunoglobulins – largest share due to broad therapeutic use
- Albumin – widely used in critical care and surgical settings
- Coagulation factors – essential for bleeding disorders like hemophilia
Immunoglobulins dominate due to increasing diagnosis rates of immune deficiencies and expanding neurological applications.
By Application
- Immunology
- Hematology
- Neurology
- Critical care
- Rare genetic disorders
Immunology remains the leading application segment due to rising autoimmune disease prevalence and increased adoption of antibody-based therapies.
By End User
- Hospitals
- Specialty clinics
- Research institutes
- Pharmaceutical companies
Hospitals account for the largest share due to high patient volumes requiring emergency and chronic plasma-based treatments.
Discover the Complete Report Here:
https://www.polarismarketresearch.com/industry-analysis/global-blood-plasma-market
Some of the major players operating in the global market include:
- Biotest AG
- CSL
- GC Biopharma Corp
- Grifols
- Intas Pharmaceuticals Ltd
- Kedrion S.p.A.
- LFB
- Octapharma AG
- Sanquin
- Takeda Pharmaceuticals
Regional Analysis
North America
North America dominates the Blood Plasma Market due to advanced healthcare infrastructure, strong biopharmaceutical industry presence, and extensive plasma donation networks. The United States leads global plasma collection and fractionation capacity.
Europe
Europe holds a significant market share supported by strong regulatory frameworks, government healthcare support, and growing adoption of plasma-derived medicines across major countries such as Germany, France, and the UK.
Asia-Pacific
Asia-Pacific is expected to witness the fastest growth due to rising healthcare investments, increasing awareness of rare diseases, and expansion of plasma collection infrastructure in countries like China, India, and Japan.
Latin America and Middle East & Africa
These regions are gradually expanding access to plasma-derived therapies due to improving healthcare systems and growing demand for advanced biologics.
Challenges in Plasma-Derived Therapies
Despite strong growth, several challenges persist:
- Limited plasma supply and donor dependency
- High manufacturing and processing costs
- Complex regulatory approval requirements
- Supply chain vulnerabilities in global distribution
Ensuring a stable and sustainable plasma supply remains one of the most critical industry challenges.
Conclusion
Plasma-derived therapies represent a vital and rapidly expanding segment of modern medicine, offering essential treatments for life-threatening and chronic conditions. Their importance continues to grow as healthcare systems increasingly rely on biologics to manage complex diseases.
As highlighted in the Blood Plasma Market analysis by Polaris Market Research, rising demand for immunoglobulins, technological advancements in plasma processing, and expanding global healthcare infrastructure are driving sustained market growth. With continued innovation and investment in plasma collection and fractionation, plasma-derived therapies will remain a cornerstone of global therapeutic advancement.
More Trending Latest Reports By Polaris Market Research:
Medical Radiation Shielding Market
FEP Heat Shrink Medical Tubing Market
Veterinary Renal Disease Market
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)